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Alexandra Prados-Torres12, Martin Scherer13, Ulrich Thiem14,15, Hendrik van den Bussche13 and Paul P Glasziou16Abstract
Multimorbidity is a health issue mostly dealt with in primary care practice. As a result of their generalist and patient-
centered approach, long-lasting relationships with patients, and responsibility for continuity and coordination of
care, family physicians are particularly well placed to manage patients with multimorbidity. However, conflicts
arising from the application of multiple disease oriented guidelines and the burden of diseases and treatments
often make consultations challenging. To provide orientation in decision making in multimorbidity during primary
care consultations, we developed guiding principles and named them after the Greek mythological figure Ariadne.
For this purpose, we convened a two-day expert workshop accompanied by an international symposium in October
2012 in Frankfurt, Germany. Against the background of the current state of knowledge presented and discussed at
the symposium, 19 experts from North America, Europe, and Australia identified the key issues of concern in the
management of multimorbidity in primary care in panel and small group sessions and agreed upon making use of
formal and informal consensus methods. The proposed preliminary principles were refined during a multistage
feedback process and discussed using a case example. The sharing of realistic treatment goals by physicians and
patients is at the core of the Ariadne principles. These result from i) a thorough interaction assessment of the
patient’s conditions, treatments, constitution, and context; ii) the prioritization of health problems that take into
account the patient’s preferences – his or her most and least desired outcomes; and iii) individualized management
realizes the best options of care in diagnostics, treatment, and prevention to achieve the goals. Goal attainment is
followed-up in accordance with a re-assessment in planned visits. The occurrence of new or changed conditions,
such as an increase in severity, or a changed context may trigger the (re-)start of the process. Further work is
needed on the implementation of the formulated principles, but they were recognized and appreciated as import-
ant by family physicians and primary care researchers.
Please see related article: http://www.biomedcentral.com/1741-7015/12/222.
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Multimorbidity, the co-occurrence of multiple chronic
conditions in an individual, is a health issue mostly dealt
with in family practice [1-4]. As a result of their general-
ist and patient-centered approach, long-lasting relation-
ships with patients, and responsibility for continuity and
coordination of care, family physicians are particularly
well placed to manage patients with multimorbidity [5].
However, physicians can feel overwhelmed by multi-
morbidity, specifically the challenges of identifying
the inter-dependence between current and continuing
problems, managing multiple changing conditions, and
the interplay between psychosocial issues (including
motivation and empowerment) and therapeutic and
prognostic aspects [6-8].
Patients with chronic diseases often suffer from the
cumulative burden of their treatments as well as any
primary and secondary prevention, prompting a call
for a minimally disruptive medicine approach [9,10].
The potential mismatch between patients’ and doctors’
preferences and priorities [11] and conflicts between
single-disease guideline recommendations make each
consultation with a patient who has multimorbidity
more demanding than those with patients with a single
disease [6,8,12-14]. Although family physicians have
devised ways to manage patients with multimorbidity,
it is rarely actively considered in medical decision
making [15].
To unpick the complexity of the management of
multimorbidity, we can focus on the decisions made by
patients and doctors during consultation. One model
of the decisions required in a comprehensive model of
primary care consultations was developed by Stott
and Davis in the 1970s, and is still taught and applied
[16]. Given that current disease-oriented guidelines
do not account for the interactions between the differ-
ent diseases [12,17], a framework for a different con-
sultation model was recently proposed for geriatric
patients with multimorbidity [18]. This approach has
yet to be considered for patients in primary care con-
sultations that require a longitudinal and comprehen-
sive approach [5,19,20]. Therefore, we set out to
develop a tool to support decision-making during
consultations in primary care that involve patients with
multimorbidity.
Process of development
Rather than use a formal consensus approach, we designed
a process aimed at fostering the re-conceptualization
of medical decision making in patients with multimor-
bidity in primary care. Our description of methods
aims to raise the transparency of this informal, multi-
stage process. For the initial development process
we convened a two-day expert workshop, which waspreceded by an international symposium in October
2012 in Frankfurt, Germany. The first phase consisted
of a one-day symposium to provide an initial exchange
of ideas between speakers, and a wider audience. At
the symposium, the current state of knowledge on
the prevalence and patterns of multimorbidity, the
complex problems of multimorbidity management and
its associated polypharmacy, the inappropriateness of
disease-oriented clinical practice guidelines, and the
challenges involved in applying evidence-based medi-
cine to individual patients with multimorbidity were
summarized within 12 presentations and discussed with
a broad international audience (for the detailed pro-
gram, see: [21]). Following the symposium, nineteen
workshop participants from six countries (Australia,
Canada, Germany, the Netherlands, Spain, and the UK)
used panel and small group discussions to identify the
key issues of concern relating to medical decision
making in patients with multimorbidity in primary care.
The workshop participants represented the fields of
primary care, public health, and geriatrics – with a
focus on epidemiology, evidence-based medicine, and
methodology. The discussion was facilitated by an inde-
pendent moderator who used both informal and formal
techniques (e.g., nominal group processes). Over the
following eight months, we drafted the principles. In
June and July 2013, we circulated the proposed prelim-
inary results to practicing family physicians and other
experts in six countries and asked for a structured feed-
back on appropriateness, feasibility, and comprehen-
siveness in the form of ratings and free text comments.
Taking into consideration the results of the written
external feedback of 24 respondents (Additional file 1),
we refined the principles. Written informed consent
was obtained from the patient/participant for publica-
tion of their individual details in this manuscript. We
then discussed the refined principles with other family
physicians and independent experts in four group
discussions that took place at Gold Coast and Newcas-
tle (Australia) and Frankfurt/Main and Bad Schwalbach
(Germany) using the case example. The key issues that
came to light during the group discussions were passed
on to all authors and agreement was sought on neces-
sary changes to the manuscript. This paper reports on
the key principles that emerged from this 14-month
iterative process to provide guidance on multimorbidity
management for family physicians in their context-
specific clinical decision making.
Tasks of primary care consultation
Stott and Davis described a widely used framework
aimed at helping family physicians to broaden the con-
sultation beyond the presenting complaint with the four
following elements: i) management of the presenting
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modification of help-seeking behaviors, and iv) oppor-
tunistic health promotion [16].
Management of the presenting problem(s)
Dealing with newly presented problems may be compli-
cated by the presence of multimorbidity, as the presenting
problem might arise from one of the patient’s existingA
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Figure 1 Life-time medical history of Mr. P. T1 to T3: Visits with patient
prostatic hyperplasia; CAD, Coronary artery disease; CCl4 Intox., Accident
Diabetes mellitus; H, Hypertension; P, Parkinson disease; Pn, Peripheral ne
living at home with his wife. The course of his medical history is depicted
T3): At T1, Mr. P is 52 years old and the main focus of his medical care lie
level and blood pressure on a daily basis. He takes oral hypoglycemics an
control he uses inhalers. His benign prostatic hyperplasia is only mildly sy
admitted to hospital with angina pectoris. A two-vessel coronary artery d
percutaneous coronary intervention that included stent implantation (St
angina pectoris. Another Stent-PCI is conducted and a beta-blocker is pr
syndrome and a peripheral neuropathy have been newly diagnosed. The
Mr. P is 75 years old. He presents with a cough, problems swallowing and
blood pressure, and low mood. He needs help with most activities of dai
(encompassing 14 oral drugs, and two inhalers with seven times daily do
changed completely. The administration of amantadine resulted in urina
catheter. After drug withdrawal, the catheter could be removed. He has p
Parkinson’s (reduced stiffness, coughing, and back pain; no problems wit
mood, a treatment plan consisting of 12 drugs, six times a day, and no o
pressure. To date, he has no cognitive deficits and conducts all (instrume
external support. He practices physical exercise daily and is well integratediseases or from treatments of those diseases. In our
case example (Figure 1), Mr. P’s presenting problem of
symptomatic fluctuating blood pressure might have
been caused by his Parkinson’s disease or was perhaps
due to inappropriate antihypertensive medication; more-
over, his cough may have indicated a deterioration in his
Parkinson’s disease, or a potential worsening of his
asthma due to treatment with beta-blockers.T1
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at three different times (see text). AoI, Aortic insufficiency; B, Benign
al intoxication with carbon tetrachloride; ChE, Cholecystectomy; D,
uropathia. Mr. P is a 77-year-old, married and highly educated man
in Figure 1. We selected three periods of Mr. P’s history (T1, T2, and
s on his diabetes and hypertension. He measures his blood glucose
d antihypertensives, and follows dietary restrictions. For asthma
mptomatic. At T2, Mr. P is a 71-year-old pensioner who has been
isease (CAD) is diagnosed, and Mr. P is discharged after a
ent-PCI) at one vessel. Ten months later, he is re-admitted with
escribed due to the CAD progression. Since T1, a primary Parkinson
number of prescriptions has risen from 5 oral drugs to 11. At T3,
hypersalivation, increased stiffness, severe back pain, fluctuating
ly living and finds it increasingly difficult to follow his treatment plan
sing). At a special care unit for Parkinson’s, his medication has been
ry retention, requiring the insertion of a transitory indwelling urine
hysical therapy and is discharged with reduced symptoms of
h hypersalivation and swallowing), increased functionality and
ngoing problems of urinary retention or fluctuations in blood
ntal) activities of daily living with reduced speed but without
d socially.
Muth et al. BMC Medicine 2014, 12:223 Page 4 of 11
http://www.biomedcentral.com/1741-7015/12/223Management of continuing problems
Patients with multimorbidity will also require attention
to ongoing management of their other problems,
including a check on progress, adherence to treatment,
and any mention of secondary prevention. This will
compete for time during the consultation, and require
careful prioritization. In our case example, Mr. P’s may
also require attention to his Parkinson’s disease or
asthma.Modification of help-seeking behavior
Every doctor-patient encounter should conclude by
checking and negotiating the patient’s needs and expec-
tations with regard to future consultations, including
routine visits and ‘safety netting’. It is important to
avoid an excessively high treatment burden of patients
that interferes with their daily life and results in adher-
ence problems with treatments and appointments,
both for presenting problems and ongoing diseases. For
example, Mr. P is highly motivated and adheres to
his treatment plan. However, at T3 he was unable to
cope with either the treatment plan or ambulatory
appointments.
Opportunistic health promotion
Preventive activities should include appropriate age- and
sex-specific prevention, but the presence of multimorbid-
ity may overload patients and physicians. For instance, for
Mr. P, at least seven primary prevention measures areTrigger, e.g. new or 
changed disease,
changed context
Follow-
up
R
tre
Int
ass
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management
Figure 2 Ariadne principles.recommended including a screening for colon cancer,
osteoporosis and kidney disease, and visual and hearing
impairment, as well as a fall assessment and a compre-
hensive eye examination [22].The Ariadne principles of counseling for patients with
multimorbidity
In Greek mythology, Ariadne helped Theseus to find his
way out of the Minotaur’s labyrinth by giving him a ball
of thread – a picture that fits in well with multimorbid-
ity research [23]. Our Ariadne principles can be viewed
as the thread that helps the physician to find his/
her way within the labyrinth of multiple primary care
consultations and (patient) contacts to other health
care professionals. Often, it is not feasible (nor desir-
able) to work-up all elements of a consultation within
one appointment. Our principles are not limited to
one consultation, but are expected to be applied con-
tinuously while emphasizing certain aspects in each
consultation.
Figure 2 represents the core elements of an ongoing
counseling process for patients with multimorbidity in
primary care. Central to the process is the sharing of
realistic treatment goals by physician and patient. They
result from a thorough interaction assessment of condi-
tions and treatments – a necessary starting point for
both presenting and continuing problems – and a
prioritization of health problems that takes into ac-
count patient preferences. Individualized managementealistic
atment
goals
eraction 
essment
Prioritization
and patient‘s
preferences
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and treatment, but also in primary and secondary
prevention) to achieve the goals. Goal attainment is
followed-up in accordance with a re-assessment during
planned visits. The occurrence of new or changed con-
ditions, such as an increase in severity, or a changed
context of the patient may provoke the (re-)start of the
process. The main forces driving the care of patients
with multimorbidity are interacting conditions (and
treatments), as opposed to patients with a single dis-
ease (even if complicated). The process is not neces-
sarily sequential, as patient’s preferences may change
over time, or the individualized management may have
to be corrected, e.g., due to arising intolerable side
effects.
Interaction assessment
In contrast to patients with single diseases, in patients
with multimorbidity a broad variety of potential inter-
actions between diseases and treatments may occur
which may worsen the course of the disease(s), cause
(avoidable) symptoms, and complicate diagnostic work-
up as well as treatment and prevention [24]. Therefore,
relevant mechanisms which have to be checked separ-
ately are drug-drug, drug-disease, and disease-disease
interactions. Apart from possible adverse drug effects,
which are more likely in multiple medications [25],
complex medication regimens should trigger awareness
of the increased risk of reduced adherence or under-
treatment that are both typical risks of polypharmacy
[26,27].
It is important to keep a list of all individual diagno-
ses and to assess their severity and impact on quality of
life and functioning. Symptoms such as pain, fatigue,
shortness of breath, or dizziness have a great impact
on quality of life and life satisfaction and thus – likely –
on patient preferences [28]. Medication that is currently
being taken should be reviewed regularly [29], and
along with the assessment of overall treatment burden,
including pharmacological and non-pharmacological
treatments, a list of other physicians and therapists
involved in the patient’s care should be updated.
An active monitoring for signs and symptoms of
psychological problems, mental disorders, and cogni-
tive dysfunction is essential, as is the identification of
social circumstances that may influence care seeking,
patient health, and the need for assistance in activities
of daily living [30,31]. In patients with multiple dis-
eases, the balance between resources and burden may
be disrupted by diseases, such as depression, anxiety,
or by contextual circumstances (living conditions, level
of social support, loneliness, or financial constraints)
[1,9,32]. Health literacy is challenged when complex
health regimens are put in place. Patients’ socialparticipation, functional autonomy, coping strategies,
and health care-seeking behavior should also be elicited
and considered, as these provide valuable contextual
information that may support clinical decision making
and care planning.
Prioritization and patient’s preferences
If the interactions of planned treatment result in more
harm than good, or treatment goals compete with one
another, or the total treatment burden is inacceptable,
then priorities must be set. Such health care decisions
need to be made within the context of patients’ values
and preferences. Patient’s preferences should be thor-
oughly elucidated, and priorities and realistic treatment
goals should be agreed upon. Family physicians should
be aware of their own potentially differing preferences
[11] that may be the result of extrinsic factors, such as
the fear of financial or legal threats.
The patient’s prognosis, in terms of physical and
mental functioning, quality of life, and life expectancy,
should always be taken into consideration [18]. Health
outcomes shift from disease-specific to generic and pa-
tient’s values often swing from life expectancy to quality
of life. Family physicians may assess preferences on the
basis of a discussion and rank the outcomes accordingly
[33]. Patients may prioritize desired outcomes, such as
symptom relief, preservation of physical, mental, and
social functioning, or disease prevention, but also the
avoidance of adverse outcomes, such as nausea, drowsi-
ness, dizziness, lethargy, or confusion [34]. Family phy-
sicians should enquire about these preferences but also
assess the acceptance of several treatments and the
ability of the patient to manage them [9,32]. Clarifying
the patient’s preferences will require an understanding
of their concerns – is it the symptoms or the potential
consequences that trouble them most? Although, pa-
tients may want more (or less) responsibility for their
health decision [35,36], a neglected preference can be
harmful [37].
The treatment goals should ideally be defined in
terms of time, that is, at what point in time this goal
should be reached or a benefit obtained. Such clarifica-
tions may support monitoring and re-discussing
priorities when goals are not attained or not at the
expected time. In particular, in typically long-lasting
family physician-patient relationships [19], preferences,
priorities, and treatment goals have to be re-assessed
regularly, as they may change, or even be reversed
when, for example, new diseases develop or contextual
changes occur [38].
Individualized management and follow-up
After the prioritization of problems, a care plan which
sets out monitoring, treatment, prevention, and (self-)
harm
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Figure 3 A general model for treatment decisions. (a) A net benefit only occurs when the individual patient’s risk or disease severity is
sufficiently high to be to the right of the treatment threshold, where the benefit and harm lines cross. (b) In most cases, there is no clear
cut-off between recommended and not recommended treatments. For example, for a patient with both rheumatoid arthritis and heart failure,
any benefit of non-steroidal anti-inflammatory drugs needs to be weighed against the higher risk of fluid retention and its effects on heart
failure [41]. (c) Some chronic diseases, in particular renal and liver failure, narrow the therapeutic window of many drugs and hence increase
the likelihood of harm. (d) Chronic diseases can attenuate the relative benefit of treatment such as statin therapy in patients with chronic kid-
ney disease receiving dialysis [42].
Muth et al. BMC Medicine 2014, 12:223 Page 6 of 11
http://www.biomedcentral.com/1741-7015/12/223management advice should be developed to meet
shared and realistic treatment goals. A central issue is
whether the expected benefits of an intervention
(diagnostic, therapeutic, or preventive) outweigh the
likely downsides and harms to the individual patient.
As a general rule, ‘single-disease’ patients with more
severe diseases or at a higher risk of negative health
outcomes, have a greater potential for benefit. Hence,
benefits are more likely to outweigh harms; whereas
low risk patients may expect less benefit but are
exposed to the same potential harms [39]. Multimor-
bidity can complicate this simple model by modifying
the patient’s risk, harms, or even the potential treat-
ment benefits. The modifying factors can include both
the chronic diseases themselves and their treatment
(Figure 3). Furthermore, time to benefit should be con-
sidered, taking into account the patient’s preferences and
expected survival [40].
The simple model may be complicated with multi-
morbidity by drug-drug, drug-disease, and disease-
disease interactions, and further complicated by the
paucity of data about their extent. The first consequenceis that we should generally be more conservative when
introducing additional treatments while at the same
time remaining aware of the risk of under-treatment.
Secondly, we have to anticipate unintended conse-
quences of any new treatment that is to check for
potential interactions ex ante and ex post (follow-up).
The identification of interactions can be facilitated
through collaboration with community pharmacists and
the optimal use of technology. User-friendly applica-
tions, such as optimized support systems alerting for
potentially inappropriate medication or interactions,
are useful, but are incomplete without a judgment of
their clinical relevance. Thirdly, complex medication
regimens are challenging for patients to comply with.
Sometimes simple solutions exist, such as altering prep-
arations to modified release formulations or using
simple prompts or reminders (e.g., dosette boxes) to
assist patients.
The careful coordination of care – the often neces-
sary involvement of different health care professionals
at different levels and settings of care – is an important
component of individualized care and should ensure
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applying a minimally disruptive approach [9] to meet-
ing agreed treatment goals. Care plans for patients
with multimorbidity are not static, but subject to
continuous adaptation depending on changes in the
prioritization of problems, goal attainment, or as a
result of co-occurring events or altering contexts. It is
also important that the patient has a family physician
in charge of his overall health process [19]. Family
physicians should be aware of new triggers (Figure 2),
which should guide the focus of the following
consultations.Reflections on the case of Mr. P
At T2 (Figure 1), a beta-blocker was prescribed to Mr. P
to slow down the progression of his coronary artery
disease. This benefit outweighed potential harms of
worsening his asthma. Mr. P agreed and his physician
provided instructions for safety netting and regular
follow-ups. At T3, a potential interaction between the
beta-blocker and asthma was ruled out by lung function
testing, and his cough was considered to be a symptom
overlap caused by his deteriorating Parkinson’s disease.
However, the ambulatory intensification of drug therapy
led to new problems. Mr. P agreed to admission to spe-
cialized care. Although complicated by an adverse drug
event due to a drug-disease interaction (amantadine
and benign prostatic hyperplasia), his situation finally
improved.
Over his life-course, treatment goals shifted from
disease-specific (e.g., blood glucose) to generic (e.g., phys-
ical functioning). Mr. P still has a strong preference
for survival (at good quality), and is willing and cap-
able of coping with his diseases and treatment burden.
In accordance with this and his general prognosis,
prioritization has not led to a de-intensification of his
treatment but to a critical selection of further preventive
activities.Discussion
We have formulated a comprehensive longitudinal
approach to the goal-oriented management of patients
with multimorbidity in primary care, i.e., an approach
addressing multiple consultations. For the heterogeneous
group of patients with multimorbidity, there are no easy
solutions that apply to all patients. Therefore, we have
developed a set of principles that can be used to
structure and enrich the approach to consultations as
suggested by Stott and Davis and to improve patient
outcomes using tailor-made approaches.
Clinicians and patients should realize that in a com-
plex situation with multiple diseases and several treat-
ments, there is no ‘single best’ choice of treatments.This may be the case with treatments which may have
beneficial effects to one disease and the potential to
cause harm in another at the same time. Although,
physician and patient share the decision for this
option, this does not necessarily prevent negative
consequences. In other circumstances, patient and
physician may share a decision against an effective
therapy in order to reduce the treatment burden. This
decision may well result in a preventable major event.
Only little is known about patients and caregivers
coping with the negative consequences of such actions
[34,43].
Our principles are not intended to support a unidir-
ectional de-intensification of treatment: a thorough
assessment of presenting and continuing problems may
identify under-treatment, or the need for intensifica-
tion, and the elucidation of patient’s preferences may
show that the patient does not perceive multiple drugs
as an unbearable burden. Prioritization is a process of
assigning priorities to problems or tasks but does not
necessarily mean a reduction.
Furthermore, our principles support a critical approach
to guidelines in a patient with multimorbidity, as we have
currently little to replace them [44]. The application of
guidelines may be safe and effective when potential
interactions are checked for, shared treatment goals are
met, and the effects are closely followed-up on. In
patients with multimorbidity, the use of guidelines will
have to be further considered and more selective to
prevent clinical management from being “inappro-
priately driven by algorithmic protocols, top-down
directives and population targets” [45]. This may also
have consequences for guideline-based processes such
as disease management programs and financial incen-
tives in health care systems.
Limitations and implications for further research
We do not pretend to have a final solution to the
complex problem of managing patients with multimor-
bidity in primary care for several reasons. Firstly,
although we received feedback from GPs and primary
care researchers, the application of the proposed key
principles has not yet been tested and the development
process did not involve the patient. Implementation
may also be difficult to achieve within the constraints
of a 10 minute consultation, but it may be possible
to integrate it into existing models of care (e.g., the
Chronic Care Model [46,47]) and develop interven-
tions within (pro-active) primary care teams and across
health care providers which may be effective in multi-
morbidity management [48]. Secondly, multimorbidity
in itself is not a homogeneous condition. Not only the
number and severity of conditions, but also other
factors such as social issues or mental illness may
Box 1: The Ariadne principles – practical hints
Assess potential interactions – the patient’s conditions
and treatments, constitution and context
 Keep a list of all current conditions, assess their severity and
impact, and review the medication currently taken.
 Actively monitor for signs of anxiety, distress and
depression, or cognitive dysfunction, including problems of
addiction and non-specific signs or symptoms such as
sleeping problems, loss of appetite, or hydration problems.
 Elicit and consider social circumstances, financial
constraints, living conditions and social support, health
literacy, functional autonomy, and coping strategies.
 List other physicians and therapists involved in the patient’s
care and assess overall treatment burden.
Elicit preferences and priorities – the patient’s most
and least desired outcomes
 Elicit preferences for generic health outcomes, such as
survival, independence, pain, and symptom relief including
palliative care needs, and be aware of your own (implicit)
preferences, as they may not be the same as the patient’s.
 If applicable, consider preferences of informal caregivers
or family.
 Agree on a realistic treatment goal with the patient (and
patient’s caregiver if appropriate).
Individualize management to reach the negotiated
treatment goals
 Weigh up whether the expected benefits of treatment (and
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mentation of these principles is rendered more com-
plex by our current modest evidence-base and limited
theory.
Given these limitations, the core elements of the
Ariadne principles outlined in Figure 2 suggest several
research priorities. The interaction assessment may
be disappointing due to the shortcomings in the
evidence about interactions and their clinical rele-
vance. High-quality and integrating information tech-
nology systems could help, but further work is needed
to optimize the benefit of this modality [51,52]. Fur-
thermore, the gap of knowledge and development
of proper theoretical models on the prioritization
hamper this process. Although patient preferences are
embraced in concepts such as patient-centeredness
and goal-oriented care [53], little is known about
how to elicit (and construct) patient’s health-related
preferences when multiple trade-offs complicate the
decision and on how patients cope with negative
consequences. In addition, evidence is sparse on the
methods and impact of individualized management.
Outcomes studied are often disease-specific and less
meaningful for decision making in patients with multiple
diseases [54].
Our principles may encourage physicians to actively
consider multimorbidity when making medical decisions.
However, the principles need further critical reviewing,
followed by empirical testing using case vignettes, case
conferences, role plays, and directly observed consulta-
tions, involving GPs and patients. In addition, further
work on prioritization is necessary to gain a better
understanding of determinants and decision-making
processes, and to provide appropriate tools supporting
interaction assessment and a communication process
that results in physician and patient sharing realistic
treatment goals.prevention) outweigh the likely downsides and harms, given
the individual patient’s risk level and preferences.
 Assess the incremental and combined treatment burden of
the patient (and caregiver, if applicable).
 Consider self-management according to the patient’s needs
and capabilities.
 Provide instructions for safety-netting such as symptoms of
side effects and recommendations about the appropriate
management.
 Agree with the patient on the schedule for follow-up visitsConclusions
We have developed the Ariadne principles to be
adopted by family physicians in daily practice. These
principles may also be incorporated into educational
programs on the care of patients with multimorbidity in
both medical education and vocational training. The
further refinement and elaboration of these principles
should be based on experiences gained from their
practical application.to evaluate goal attainment and re-assess interactions.
 Consult other health care providers and informal caregivers
who are involved with the patient. Ideally, all health care
providers involved are informed about treatment decisions
or have access to information.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
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